Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.The healthcare sector's latest quarterly-earnings parade kicked off on Tuesday with a report from Johnson & Johnson (JNJ 1.55%) that was somewhat mixed. As is often the case, the purveyor of pharmaceuticals and medical technology exceeded Wall Street estimates on the top and bottom lines.The average analyst following J&J expected the company to earn an adjusted $2.21 per share, but it reported a muc ...